While both molecules efficiently slowed down disease progression in the Han:SPRD cy/+ rat [199,200,201] and rapamycin further proved to be efficient in the bpk mouse and the orpk-rescue mouse [202], no beneficial effect of rapamycin or everolimus treatment could be observed in clinical trials with ADPKD patients [203,204]. The gene discussed is BTK; the disease is autosomal dominant polycystic kidney disease.